The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
The NCPE does not recommend reimbursement of Teduglutide (Revestive®) for the treatment of patients aged 1 year and above with short bowel syndrome.
The NCPE are delighted to facilitate the delivery of the HTA module of the IPPOSI Pilot Patient Education Programme, commencing this Monday 22nd January. This module will provide students with a detailed knowledge of the principals of HTA, and has been adapted by the NCPE to provide particular insight into the practice of HTA in […]
The NCPE does not recommend the reimbursement of Nusinersen (Sprinraza®) for the treatment of 5q spinal muscular atrophy (SMA) at the submitted price.
The NCPE does not recommend reimbursement of Ixazombi (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
The NCPE do not recommend reimbursement of PROCYSBI for the treatment of nephropathic cystinosis patients.
The NCPE do not recommend reimbursement of Obeticholic acid (Ocaliva®) at the submitted price.
The NCPE do not recommend reimbursement of Pembrolizumab (Keytruda®) for NSCLC (first line) at the submitted price.
Reimbursement not recommeded.
Following NCPE assessment of the applicant’s submission, cost effectiveness of palbociclib (Ibrance®) for this indication has not been demonstrated, and therefore is not recommended for reimbursement.